痛泻要方颗粒治疗腹泻型肠易激综合征的疗效及全转录组分析:随机对照试验方案
本研究为随机双盲安慰剂对照试验,计划纳入120例腹泻型肠易激综合征(IBS-D)患者,随机分入痛泻要方颗粒组或安慰剂组,另招募10名健康人作为机制研究对照。主要结局为IBS症状严重程度量表(IBS-SSS)应答率,机制结局为肠道黏膜全转录组分析。
要点
- 痛泻要方颗粒治疗IBS-D的疗效与安全性将获高质量证据验证。
- 全转录组分析旨在揭示IBS-D的基因层面机制及痛泻要方的作用靶点。
- 试验包含2周导入期、12周治疗期和8周随访期。
核心结论
- 本试验旨在验证痛泻要方颗粒治疗IBS-D的疗效与安全性,并通过全转录组分析阐明其分子机制及潜在生物标志物。
研究设计与样本
- 随机、双盲、安慰剂对照临床试验,包含2周导入期、12周治疗期和8周随访期。
- 计划纳入120例IBS-D患者,随机分为痛泻要方颗粒组和安慰剂组,另招募10名健康人作为机制研究对照。
关键数值与推荐
- 主要结局为IBS症状严重程度量表(IBS-SSS)的应答率。
- 次要结局包括充分缓解(AR)、IBS生活质量问卷(IBS-QOL)和长期疗效。
- 机制结局为IBS患者治疗前后及健康人肠道黏膜的全转录组分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Irritable bowel syndrome (IBS) is one kind of common functional bowel disease with obscure pathogenesis, and exploration about whole transcriptome profiling in IBS-D is still negligible. Conventional medications have limited effects, which makes focus shifted to traditional Chinese medicine (TCM). Tong-Xie-Yao-Fang, as a classic herbal formula in TCM, is pretty effective and safe for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D), but the underlying therapeutic mechanism remains unknown. We aim to verify the efficacy and safety of TXYF granule (the formula particles mixed together) in IBS-D and elucidate the gene-level mechanism of IBS-D and therapeutic targets of TXYF granule based on whole transcriptome analysis. METHODS/DESIGN: This is a randomized, double-blind, and placebo-controlled clinical trial consisting of 2 weeks of run-in period, 12 weeks of treatment period, and 8 weeks of follow-up period. We will enroll 120 participants with IBS-D, who will be randomly assigned to the TXYF granule group and the placebo group, and recruit additional 10 healthy individuals as controls for mechanistic outcome. The two groups respectively take TXYF granule or placebo orally for treatment. The primary outcome is the response rate of IBS-Symptom Severity Score (IBS-SSS). The secondary outcomes include adequate relief (AR), IBS-Quality of Life Questionnaire (IBS-QOL), and long-term efficacy. Mechanistic outcome is the whole transcriptome profiling of the intestinal mucosae from IBS participants before and after the treatment and healthy individuals. DISCUSSION: This trial will prove the effectiveness and safety of TXYF granule with high-quality evidence and provide a penetrating and comprehensive perspective on the molecular mechanism of IBS-D by whole transcriptome analysis, which makes us pinpoint specific biomarkers of IBS-D and therapeutic targets of TXYF. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR-IOR-1900021785 . Registered on 9 March 2019.
引用
- Wang Y, Huang YQ, Zhu SL, et al. Efficacy of Tong-Xie-Yao-Fang granule and its impact on whole transcriptome profiling in diarrhea-predominant irritable bowel syndrome patients: study protocol for a randomized controlled trial. Trials. 2020. PMID: 33143731. doi:10.1186/s13063-020-04833-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。